Gonzales Holly, Richardson Travis D, Montgomery Jay A, Crossley George H, Ellis Christopher R
Cardiovascular Division, Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
J Innov Card Rhythm Manag. 2019 Dec 15;10(12):3930-3936. doi: 10.19102/icrm.2019.101204. eCollection 2019 Dec.
Pacemaker-dependent (PD) patients undergoing implantable cardiac electronic device extraction often must be subjected to temporary pacing interventions. We sought to determine the safety and utility of a leadless pacing system (Micra™; Medtronic, Minneapolis, MN, USA) in patients undergoing system extraction as compared with externalized temporary transvenous right ventricular lead (temp-perm) placement. We performed a retrospective cohort analysis of all patients receiving either permanent Micra™ or temp-perm systems following system extraction from October 2013 to September 2017 at Vanderbilt University Hospital. The Micra™ and temp-perm cohorts included nine and 27 patients meeting the inclusion criteria, respectively. System infection was the most common indication for extraction (67% Micra™, 84% temp-perm), but no patients had active bacteremia at the time of permanent system reimplantation. There was no difference in system type (p = 0.09) or mean lead dwell time extracted (109 versus 81 months; p = 0.93). Procedure times were comparable between the two groups (180 versus 194 minutes; p = 0.74). Patients receiving Micra™ systems had shorter hospital stays after extraction (two versus eight days; p < 0.005), with no difference in major complications (11% versus 15%; p = 0.78) or 30-day (11% versus 7%; p = 0.77) or 90-day (11% versus 11%; p = 0.45) mortality. No reinfections were observed in either group at 90 days. Implantation of the Micra™ pacing system in select PD patients after system extraction is feasible and appears to reduce the hospital length of stay as compared with the use of temp-perm systems.
接受植入式心脏电子设备拔除的起搏器依赖(PD)患者通常必须接受临时起搏干预。我们试图确定与外置临时经静脉右心室导线(临时-永久)置入相比,无导线起搏系统(Micra™;美敦力公司,美国明尼苏达州明尼阿波利斯)在接受系统拔除的患者中的安全性和实用性。我们对2013年10月至2017年9月在范德比尔特大学医院接受系统拔除后植入永久性Micra™或临时-永久系统的所有患者进行了回顾性队列分析。Micra™组和临时-永久组分别有9例和27例患者符合纳入标准。系统感染是拔除的最常见原因(Micra™组为67%,临时-永久组为84%),但在永久性系统重新植入时没有患者出现活动性菌血症。系统类型(p = 0.09)或拔除的平均导线留置时间(109个月对81个月;p = 0.93)没有差异。两组的手术时间相当(180分钟对194分钟;p = 0.74)。接受Micra™系统的患者拔除后住院时间较短(2天对8天;p < 0.005),主要并发症(11%对15%;p = 0.78)或30天(11%对7%;p = 0.77)或90天(11%对11%;p = 0.45)死亡率没有差异。90天时两组均未观察到再感染。在部分PD患者系统拔除后植入Micra™起搏系统是可行的,并且与使用临时-永久系统相比,似乎可以缩短住院时间。